KRAS and non-small cell lung carcinoma: Smoking‐related KRAS mutations are the most common carcinogenic change in NSCLC.6, 7 Recent clinical evidence indicates that tumors classified as KRAS‐TP53 have an immunogenic phenotype and may be more sensitive to nivolumab.8